One of the most important developments in longevity medicine over the past five years is the shift from senolytics being a theoretical concept to having actual human tissue data. The basic idea has been around since 2015: as we age, certain cells stop dividing but refuse to die. These 'senescent cells' accumulate and continuously secrete a cocktail of inflammatory molecules — the Senescence-Associated Secretory Phenotype, or SASP — that damage surrounding tissue and, critically, suppress the body's own regenerative capacity.
In 2025 and 2026, the field moved meaningfully. The question is no longer 'does this idea make sense' — it does, mechanistically — but 'what can we actually do about it clinically, and what does the evidence say?'
The Stem Cell Connection: Why Senolytics Are Relevant to Regenerative Medicine
A 2025 NIH review demonstrated something that connects senolytics directly to stem cell therapy: SASP cytokines from senescent cells directly suppress endogenous stem cell activity. One cited finding: IL-6 secreted by senescent cells reduced neurogenesis by 63% in an experimental model. Applied more broadly, this means that the accumulated senescent cell burden in aging tissues may be one reason why the body's own regenerative responses weaken with age.
This has a practical implication. If senescent cells are suppressing local stem cell activity, then introducing exogenous stem cells (as in MSC therapy) into a tissue environment loaded with SASP signals may produce suboptimal results — because the injected cells encounter the same hostile environment that suppressed the body's own. The theoretical 'clear the field, then regenerate' strategy follows directly from this logic.
Dasatinib + Quercetin: The Best-Studied Senolytic Combination
Dasatinib (a cancer drug repurposed at lower doses) and quercetin (a plant-derived flavonoid) together form the most studied senolytic combination in humans. A 2025 study published in Aging Cell used human osteoarthritic cartilage tissue to test whether D+Q could restore healthy cartilage cell behavior:
- D+Q selectively eliminated senescent chondrocytes from human OA cartilage
- Significantly upregulated COL2A1, ACAN, and SOX9 — genes responsible for cartilage matrix production
- Increased collagen type II and glycosaminoglycan biosynthesis
- Reduced markers of cartilage breakdown
This was done on human OA tissue — not mice — making it clinically relevant. The authors described D+Q as a 'promising candidate for further testing as a disease-modifying osteoarthritis drug.' Whether these tissue-level improvements translate to meaningful patient outcomes in randomized trials remains to be established.
What Phase 1/2 Human Trials Show
D+Q has been tested in Phase 1/2 trials for idiopathic pulmonary fibrosis, diabetic kidney disease, and frailty protocols. Fisetin — a senolytic available as a supplement — is in multi-center frailty studies and a Phase 1/2 trial at the Steadman Clinic specifically for knee osteoarthritis.
As of mid-2026, no senolytic has received regulatory approval for any aging-related indication. The field has produced consistent mechanistic validation and early safety data, but pivotal efficacy trials are still in progress.
The 'Clear and Regenerate' Strategy: Animal Evidence
The combination of senolytics followed by regenerative therapy has been tested in animal models with promising results — senolytic treatment creates a more permissive tissue environment, and subsequent regenerative interventions (growth factors, stem cells) produce stronger effects than in untreated animals. This combination has not been tested in human clinical trials as of 2026.
We flag this clearly because the leap from animal models to human protocols is not guaranteed. The history of regenerative medicine is full of strong animal results that did not replicate cleanly in humans.
An Important Caution About Senolytics
Senescent cells are not uniformly harmful. They play roles in wound healing, embryonic development, and tumor suppression. Broad-spectrum elimination of senescent cells system-wide carries risks — including disrupted wound healing and reduced immune surveillance. A 2026 paper in npj Aging highlighted a shift in the field toward tissue-specific and cell-type-specific senolytic targeting for this reason.
Dasatinib is an oncology drug with real immunosuppressive effects. Off-label use of it as a senolytic outside of clinical trials carries meaningful safety considerations. There is also no approved biomarker test to measure your senescent cell burden or track treatment response — meaning you cannot currently confirm whether a senolytic protocol is working.
At Rakan Clinic Tokyo
The anti-aging medicine we practice at Rakan Clinic is grounded in what the evidence supports. Our core regenerative tools — adipose-derived mesenchymal stem cell therapy, Super Rich PRP, and IV exosome therapy — all work at the level of reducing inflammation and supporting tissue repair: the same biological targets that senolytic research is converging on.
We do not offer senolytic drug protocols as part of our standard treatment menu, because the clinical evidence for approved protocols does not yet exist. What we do offer is a thorough anti-aging evaluation, biomarker assessment, and a personalized regenerative treatment plan that addresses the inflammatory and tissue-degeneration mechanisms that senolytic research has helped illuminate.
Frequently Asked Questions
What exactly are senolytics?
Senolytics are drugs or compounds that selectively trigger apoptosis (cell death) in senescent cells — cells that have stopped dividing but resist dying and continuously secrete inflammatory molecules (SASP). The most studied senolytic combination is dasatinib + quercetin (D+Q). Fisetin, a plant flavonoid, is also being studied.
Are senolytics approved for use?
As of mid-2026, no senolytic has received regulatory approval for any aging indication in any major market. D+Q is being tested in Phase 1/2 trials for specific conditions (pulmonary fibrosis, frailty, diabetic kidney disease). Fisetin is available as a supplement but without large-scale RCT evidence. Off-label use of dasatinib outside clinical trials carries real safety considerations.
Do senolytics affect stem cell therapy outcomes?
Mechanistically, yes — senescent cells secrete SASP signals that suppress stem cell activity, so reducing the senescent cell burden could theoretically create a more receptive environment for stem cell therapy. However, this combination has not been tested in human clinical trials, so clinical benefit from combining them cannot be claimed.
Can I take quercetin supplements as a senolytic?
Quercetin alone has a much weaker senolytic effect than the D+Q combination. As a supplement, quercetin has a reasonable safety profile and some anti-inflammatory benefits, but treating it as a meaningful senolytic based on current evidence would be overstating what the supplement data supports.
Does Rakan Clinic offer senolytic treatment?
We do not currently offer senolytic drug protocols as a standard treatment, because the clinical evidence does not yet support specific approved protocols. Our anti-aging assessments and regenerative medicine treatments address the same underlying mechanisms — inflammation and tissue degeneration — that senolytic research has helped define. A consultation will help determine what approaches are appropriate for your specific situation.
Ready to Learn More?
Schedule a consultation with our specialists to discuss how stem cell therapy can help you. Learn whether adipose stem cells are right for your joint condition.
